Heat Biologics, Inc.
(NASDAQ : HTBX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.37%190.841.2%$559.15m
GILDGilead Sciences, Inc.
-0.27%70.730.9%$494.42m
BIIBBiogen Inc.
-1.40%314.611.3%$442.27m
CELGCelgene Corporation
-0.52%69.871.2%$416.21m
ILMNIllumina, Inc.
-1.04%307.953.5%$394.16m
REGNRegeneron Pharmaceuticals, Inc.
-1.40%337.302.6%$277.82m
VRTXVertex Pharmaceuticals Incorporated
-3.68%164.041.9%$261.35m
ALXNAlexion Pharmaceuticals, Inc.
-1.70%116.512.0%$195.69m
AAgilent Technologies, Inc.
-1.04%63.671.5%$166.39m
EXASExact Sciences Corporation
-1.69%68.2425.3%$147.13m
LGNDLigand Pharmaceuticals Incorporated
-0.40%147.8423.3%$143.04m
SRPTSarepta Therapeutics, Inc.
-5.32%110.5616.4%$126.48m
ECYTEndocyte, Inc.
-0.04%23.572.0%$120.21m
INCYIncyte Corporation
0.28%63.912.5%$112.71m
NKTRNektar Therapeutics
1.74%38.005.6%$107.70m

Company Profile

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.